Expertise in
44
conditions

Dr. Rimas V. Lukas

Northwestern Medical Faculty Foundation
Chicago, IL
Expertise in
44
conditions
Specialties:Hematology Oncology | Neurology | Hematology
Accepting New Patients
Offers Telehealth
Expertise in
44
conditions
OverviewInsuranceLocationsClinical Research

Overview

Rimas Lukas is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Lukas is highly rated in 44 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioma, Glioblastoma, Brain Tumor, and Gastrostomy. Dr. Lukas is currently accepting new patients.

His clinical research consists of co-authoring 182 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Neurology
Hematology
Licenses
Psychiatry & Neurology in IL
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

NORTHWESTERN MEDICAL FACULTY FOUNDATION
675 N St Clair, 100 Dept Of Neurology, Chicago, IL 60611
312-695-7950

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Other, Drug, Radiation
Study Drug: Memantine
Study Phase: Phase 3
Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial
Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2024
Intervention Type: Drug, Radiation
Study Drugs: BMS-986205, Nivolumab, Temozolomide
Study Phase: Phase 1
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Drug, Biological
Study Drugs: Ad-RTS-hIL-12, Veledimex
Study Phase: Phase 1
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

182 Total Publications

Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects.
Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects.
Journal: Future oncology (London, England)
Published: January 09, 2025
Similar Doctors
Expertise in
16
conditions
Dr. Roger Stupp
Hematology Oncology | Neurology | Hematology
Expertise in
16
conditions
Dr. Roger Stupp
Hematology Oncology | Neurology | Hematology

Northwestern Medical Faculty Foundation

675 N St Clair, 200 Dept Of Otolarynglgy, 
Chicago, IL 
312-695-8182
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Roger Stupp is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Stupp is highly rated in 16 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri.

Expertise in
27
conditions
Dr. Priya U. Kumthekar
Hematology Oncology | Neurology | Hematology
Expertise in
27
conditions
Dr. Priya U. Kumthekar
Hematology Oncology | Neurology | Hematology

Northwestern Medical Faculty Foundation

675 N St Clair, 250 Dept Of Nephrology, 
Chicago, IL 
312-695-0596
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Priya Kumthekar is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Kumthekar is highly rated in 27 conditions, according to our data. Her top areas of expertise are Astrocytoma, Glioma, Brain Tumor, and Glioblastoma. Dr. Kumthekar is currently accepting new patients.

Expertise in
29
conditions
Dr. Sonali M. Smith
Hematology Oncology | Hematology | Oncology
Expertise in
29
conditions
Dr. Sonali M. Smith
Hematology Oncology | Hematology | Oncology

University Of Chicago

355 E Grand Ave, 
Chicago, IL 
 (0.4 mi)
888-824-0200
Languages Spoken:
English, Greek, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonali Smith is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Smith is highly rated in 29 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile